Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Effects of meditation and yoga on anxiety, depression and chronic inflammation in patients with Parkinson's disease: a randomized clinical trial
Kwok JYY, Chan LML, Lai CA, Ho PWL, Choi ZY-K, Auyeung M, Pang SYY, Choi EPH, Fong DYT, Yu DSF, Lin C-C, Walker R, Wong SYS, Ho RTH
Psychotherapy and Psychosomatics 2025;94(2):101-118
clinical trial
This trial has not yet been rated.

INTRODUCTION: Clinical guidelines recommend a holistic approach to Parkinson's disease (PD) care, yet randomized trials examining mindfulness-based interventions in this context are scarce. This study investigated the effects of two mindfulness practices- meditation and yoga- on biopsychosocial outcomes in PD patients, including anxiety symptoms, depressive symptoms, motor/nonmotor symptoms, health-related quality-of-life (HRQOL), mindfulness, and stress and inflammation biomarkers, compared to usual care. METHODS: 159 participants with a clinical diagnosis of idiopathic PD and a Hoehn and Yahr stage of 1, 2, and 3, were randomized into meditation (n = 53), yoga (n = 52), and control (n = 54). Meditation and yoga were delivered in 90-min groups for 8 weeks. Primary outcomes included anxiety symptoms and depressive symptoms. Secondary outcomes included motor and nonmotor symptoms, HRQOL, mindfulness, and serum levels of interleukin-6, cortisol and TNF-alpha. Assessments were done at baseline (T0), 2 months (T1), and 6 months (T2). Linear mixed models were conducted following intentionto- treat principle. RESULTS: Compared to control, both meditation, and yoga groups had significant improvements in anxiety symptoms (meditation: mean difference (MD) -1.36, 95% CI -2.46 to -0.26; yoga: MD -1.61, CI -2.70 to -0.52), motor symptoms (meditation: MD -5.35, CI -8.61 to -2.09; yoga: MD -6.59, CI -9.82 to -3.36), HRQOL (meditation: MD -2.01, CI -3.41 to -0.62; yoga: MD -1.45, CI -2.83 to -0.08), and describing skills (meditation: MD 0.97, CI 0.04 to 1.89; yoga: MD 0.92, CI 0.01 to 1.84) at T1, and significant reductions in serum interleukin-6 levels (meditation: MD -1.14, CI -2.18 to -0.10; yoga: MD -1.11, CI -2.09 to -0.13) at T2. Only meditation significantly reduced depression (MD -1.44, CI -2.57 to -0.30) at T1 and sustained the motor and HRQOL improvements at T2. CONCLUSIONS: Meditation and yoga significantly improved anxiety symptoms, chronic inflammation, motor symptoms, mindfulness-describing facet, and HRQOL in PD patients. Meditation provided additional benefits in reducing depressive symptoms and sustaining motor and HRQOL improvements.

Full text (sometimes free) may be available at these link(s):      help